[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR092532A1 - Etanercept correctamente plegado de alta pureza y excelente rendimiento - Google Patents

Etanercept correctamente plegado de alta pureza y excelente rendimiento

Info

Publication number
AR092532A1
AR092532A1 ARP130103250A ARP130103250A AR092532A1 AR 092532 A1 AR092532 A1 AR 092532A1 AR P130103250 A ARP130103250 A AR P130103250A AR P130103250 A ARP130103250 A AR P130103250A AR 092532 A1 AR092532 A1 AR 092532A1
Authority
AR
Argentina
Prior art keywords
protein
folded
correctly folded
etanercept
mixed mode
Prior art date
Application number
ARP130103250A
Other languages
English (en)
Inventor
Arakawa Tsutomu
Farrar Douglas
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR092532(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of AR092532A1 publication Critical patent/AR092532A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/165Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Método de cromatografía de modo mixto para separar las conformaciones correctamente plegadas de las incorrectamente plegadas de una proteína dada. El método es muy eficaz en la separación de etanercept correctamente plegado del etanercept incorrectamente plegado y de agregados con rendimientos comercialmente atractivos que permiten obtener preparaciones de etanercept de una muy alta pureza en términos de etanercept correctamente plegado versus etanercept incorrectamente plegado. La solicitud está dirigida además a preparaciones de proteínas y formulaciones que comprenden proteínas correctamente plegadas obtenidas usando los métodos de la presente, y métodos de tratamiento que emplean las preparaciones de gran pureza obtenidas del método de modo mixto. Reivindicación 1: Un método de cromatografía de modo mixto para separar una proteína correctamente plegada de una proteína incorrectamente plegada, que comprende los pasos de: (a) unir una primera mezcla de proteínas que comprende ambas conformaciones correctamente plegada e incorrectamente plegada de una proteína dada con una resina de cromatografía de modo mixto que tiene porciones de intercambio iónico y porciones hidrofóbicas; (b) eluir la proteína correctamente plegada de la resina de modo mixto para obtener una segunda mezcla de proteínas que Comprende una mayor proporción de proteína correctamente plegada que la primera mezcla de proteínas.
ARP130103250A 2012-09-11 2013-09-11 Etanercept correctamente plegado de alta pureza y excelente rendimiento AR092532A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
AR092532A1 true AR092532A1 (es) 2015-04-22

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103250A AR092532A1 (es) 2012-09-11 2013-09-11 Etanercept correctamente plegado de alta pureza y excelente rendimiento

Country Status (32)

Country Link
US (6) US20140072560A1 (es)
EP (1) EP2895188B1 (es)
JP (3) JP2015533797A (es)
KR (2) KR102133699B1 (es)
CN (2) CN110051823A (es)
AR (1) AR092532A1 (es)
AU (2) AU2013315750B9 (es)
BR (1) BR112015005161A2 (es)
CA (1) CA2882551A1 (es)
CL (1) CL2015000572A1 (es)
CO (1) CO7400876A2 (es)
CY (1) CY1120062T1 (es)
DK (1) DK2895188T3 (es)
DO (1) DOP2015000055A (es)
EA (1) EA031324B1 (es)
EC (1) ECSP15014138A (es)
ES (1) ES2657377T3 (es)
HR (1) HRP20180182T1 (es)
HU (1) HUE036524T2 (es)
IL (2) IL237311B (es)
IN (1) IN2015KN00452A (es)
LT (1) LT2895188T (es)
MX (2) MX360044B (es)
NO (1) NO2972131T3 (es)
PE (2) PE20150996A1 (es)
PL (1) PL2895188T3 (es)
PT (1) PT2895188T (es)
RS (1) RS57013B1 (es)
SG (1) SG11201501460RA (es)
SI (1) SI2895188T1 (es)
TW (2) TWI716649B (es)
WO (1) WO2014043103A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610839C (en) 2005-06-14 2019-06-25 Amgen Inc. Self-buffering protein formulations
MX2014004725A (es) 2011-10-18 2015-02-05 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con aminoacidos.
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CN110051823A (zh) * 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
MX2016016318A (es) * 2014-06-13 2017-06-12 Lupin Atlantis Holdings Sa Proceso para la purificacion de la proteina de fusion.
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
BR112017014224A2 (pt) 2014-12-31 2018-03-06 Lg Chem, Ltd. método para a preparação de proteína de fusão fc-tnfr que contém teor alvo de impurezas
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
KR20180083409A (ko) * 2015-11-18 2018-07-20 메르크 파텐트 게엠베하 이온 교환 크로마토그래피에서의 개선된 단백질 분리
CN108350027A (zh) * 2015-11-18 2018-07-31 默克专利股份公司 用于改进的蛋白质分离的相反的pH-盐梯度
TWI798179B (zh) * 2016-06-17 2023-04-11 美商建南德克公司 多特異性抗體之純化
CN109982685B (zh) * 2016-10-21 2022-03-11 美国安进公司 药物配制品及其制备方法
MX2019011343A (es) * 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるtnf−依存性炎症の治療方法
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
BR0108193A (pt) 2000-02-10 2003-02-25 Wyeth Corp Processo para tratamento ou inibição de dano celular ou morte celular
EP1314437B1 (en) 2000-08-11 2014-06-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
WO2002068455A2 (en) 2001-02-23 2002-09-06 Immunex Corporation Efficient recovery of correctly refolded proteins
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
WO2004017955A1 (en) * 2002-08-22 2004-03-04 Vasopharm Biotech Gmbh L-arginine containing pharmaceutical composition
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
WO2004075918A1 (en) 2003-02-28 2004-09-10 Ares Trading S.A. Liquid formulations of tumor necrosis factor-binding proteins
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
US7276477B2 (en) 2003-08-01 2007-10-02 Amgen Inc. Crystals of etanercept and methods of making thereof
EP2407470A3 (en) 2003-10-14 2015-06-10 F. Hoffmann-La Roche Ltd. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
WO2005082483A1 (en) * 2004-02-27 2005-09-09 Ge Healthcare Bio-Sciences Ab A process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトTNF−α抗体活性低下抑制剤
CN104388324A (zh) 2004-03-05 2015-03-04 帝斯曼知识产权资产管理有限公司 用于通过连续灌注和交互切向流来培养细胞的方法
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
WO2007092772A2 (en) 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
EA015992B1 (ru) 2006-03-17 2012-01-30 Байоджен Айдек Эмэй Инк. Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
JP5623743B2 (ja) 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2129401B8 (en) 2006-12-21 2020-01-15 Amgen Inc. Stable buffered formulations containing polypeptides
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
PT2115126E (pt) 2007-03-02 2015-08-24 Wyeth Llc Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
EP3461500A1 (en) 2007-06-14 2019-04-03 Biogen MA Inc. Natalizumab antibody formulations
JP5840364B2 (ja) 2007-11-30 2016-01-06 アッヴィ バイオテクノロジー リミテッド タンパク質製剤及びその製造方法
MX2010009398A (es) 2008-02-29 2010-11-12 Biogen Idec Inc Proteinas de fusion de inmunoglobulinas purificadas y los metodos para su purificacion.
US9238810B2 (en) * 2008-06-05 2016-01-19 Affibody Ab Polypeptide
WO2011015926A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
ES2817802T3 (es) 2009-08-07 2021-04-08 Emd Millipore Corp Métodos para purificar una proteína objetivo de una o más impurezas en una muestra
JP5930542B2 (ja) 2009-08-11 2016-06-08 ジェネンテック, インコーポレイテッド グルタミンフリー細胞培養培地におけるタンパク質の生産
WO2011049798A1 (en) * 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
USRE48864E1 (en) 2010-04-26 2021-12-28 Novartis Ag Cell culture medium
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
WO2012013980A1 (en) 2010-07-30 2012-02-02 Arecor Limited Stabilized aqueous antibody compositions
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
CA2807895A1 (en) 2010-08-31 2012-03-08 Friesland Brands B.V. Culture medium for eukaryotic cells
SG189872A1 (en) * 2010-10-11 2013-06-28 Abbvie Inc Processes for purification of proteins
JP5996631B2 (ja) 2011-04-20 2016-09-21 サンド・アクチエンゲゼルシヤフト TNFR:Fc融合タンパク質の安定した医薬液剤
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
KR102061355B1 (ko) 2011-07-01 2019-12-31 바이오젠 엠에이 인코포레이티드 아르기닌-없는 tnfr : fc-융합 폴리펩티드 조성물 및 이용 방법
PL2726600T3 (pl) 2011-07-01 2017-08-31 Amgen Inc. Hodowla ssaczych komórek
AU2012282960A1 (en) * 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
US9279014B2 (en) 2011-08-17 2016-03-08 Ares Trading S.A. Methods for preparing an active TNFR-Fc fusion protein
MX2014004725A (es) 2011-10-18 2015-02-05 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con aminoacidos.
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CN104661651A (zh) * 2012-07-09 2015-05-27 科荣生生物科学公司 表现出不溶性微粒显著减少的依那西普制剂
CN110051823A (zh) * 2012-09-11 2019-07-26 科荣生生物科学公司 高纯度和优异产量的正确折叠的依那西普
EP3879334B1 (en) * 2014-07-31 2023-11-29 Mtt Innovation Incorporated Numerical approaches for free-form lensing: area parameterization free-form lensing
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
AU2013315750B9 (en) 2018-11-15
EA031324B1 (ru) 2018-12-28
TW201425331A (zh) 2014-07-01
BR112015005161A2 (pt) 2017-07-04
EP2895188A4 (en) 2016-05-25
US11001627B2 (en) 2021-05-11
IL267452B (en) 2021-05-31
PE20200607A1 (es) 2020-03-10
TW201803593A (zh) 2018-02-01
CN104902914B (zh) 2019-01-01
EP2895188B1 (en) 2017-11-15
MX2018012749A (es) 2020-11-12
AU2013315750B2 (en) 2018-07-12
ES2657377T3 (es) 2018-03-05
IL267452A (en) 2019-08-29
KR20200085937A (ko) 2020-07-15
KR102133699B1 (ko) 2020-07-14
KR102250937B1 (ko) 2021-05-12
AU2018247244A1 (en) 2018-11-01
TWI716649B (zh) 2021-01-21
US10954295B2 (en) 2021-03-23
KR20150056601A (ko) 2015-05-26
LT2895188T (lt) 2018-04-10
US10947306B2 (en) 2021-03-16
JP6913066B2 (ja) 2021-08-04
DOP2015000055A (es) 2015-04-30
CN104902914A (zh) 2015-09-09
IN2015KN00452A (es) 2015-07-17
US20190300602A1 (en) 2019-10-03
AU2013315750A1 (en) 2015-03-05
MX2015003090A (es) 2015-07-14
NO2972131T3 (es) 2018-04-21
US20190300601A1 (en) 2019-10-03
RS57013B1 (sr) 2018-05-31
EP2895188A1 (en) 2015-07-22
US10954293B2 (en) 2021-03-23
US20140072560A1 (en) 2014-03-13
TWI609877B (zh) 2018-01-01
SI2895188T1 (en) 2018-05-31
US20190330325A1 (en) 2019-10-31
CO7400876A2 (es) 2015-09-30
ECSP15014138A (es) 2016-01-29
HUE036524T2 (hu) 2018-07-30
JP2021100929A (ja) 2021-07-08
CA2882551A1 (en) 2014-03-20
SG11201501460RA (en) 2015-04-29
US10954294B2 (en) 2021-03-23
DK2895188T3 (en) 2018-02-26
IL237311B (en) 2019-07-31
WO2014043103A1 (en) 2014-03-20
CL2015000572A1 (es) 2016-02-05
PE20150996A1 (es) 2015-08-01
JP2019038817A (ja) 2019-03-14
PL2895188T3 (pl) 2018-06-29
MX360044B (es) 2018-10-19
JP2015533797A (ja) 2015-11-26
AU2018247244B2 (en) 2020-05-28
HRP20180182T1 (hr) 2018-04-20
EA201590542A1 (ru) 2015-07-30
PT2895188T (pt) 2018-02-08
CY1120062T1 (el) 2018-12-12
IL237311A0 (en) 2015-04-30
US20180037642A1 (en) 2018-02-08
US20190300600A1 (en) 2019-10-03
CN110051823A (zh) 2019-07-26

Similar Documents

Publication Publication Date Title
AR092532A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento
CY1123515T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
CY1123672T1 (el) Μεθοδοι αγωγης μιας ταυπαθειας
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CY1121989T1 (el) Φαρμακοτεχνικες μορφες αντισωματων
CO2020001872A2 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EA201892693A1 (ru) Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
WO2017180917A3 (en) Lipid compositions and their uses for intratumoral polynucleotide delivery
PE20060816A1 (es) Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos
EA201890729A1 (ru) Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
AR099288A1 (es) Proteínas de fusión de interleucina-10
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
AR090884A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
EA201791350A9 (ru) Радиофармацевтические комплексы
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
MX2020000288A (es) Cromatografia.
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
BR112021019612A2 (pt) Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
BR112018017174A2 (pt) conjugados de aminoácido e peptídeo e processo de conjugação
CO2023004265A2 (es) Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
BR112012022292A2 (pt) método para produção da proteína recombinante interferon solúvel sem desnaturação.

Legal Events

Date Code Title Description
FC Refusal